414results about How to "Improve cell activity" patented technology

The invention relates to the alteration of cell properties using RNA molecules. In particular, it relates to the alteration of the ability of cells to mobilise, migrate, integrate, proliferate and/or differentiate. For example, it relates to the induction of differentiation of stem cells, including the acquisition of the ability to migrate, integrate, and proliferate. It also relates to the induction of in vivo stem cell mobilisation, migration, integration, proliferation and/or differentiation. Accordingly, it relates to the promotion of stem cell-mediated functional repair. The invention also relates to the reversal of differentiation of differentiated cells. All these effects may be effected by providing isolated RNA comprising a RNA sequence extractable from cells comprising the desired cell type(s) to a population of cells under conditions whereby the alteration of the cell property is achieved.

The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.

A method to enhance osteoblast functionality of a medical implant. The method may include obtaining the medical implant and treating a surface of the medical implant to modify the surface characteristics causing increase functionality of adjacent positioned osteoblasts. A method of increasing cellular activity of a medical implant is also disclosed. A medical device having enhanced cytocompatibility capabilities includes a metallic substrate with an outer surface. Attached to the outer surface is a composition of nanosized structures. A biosensor for use with a medical device, includes an electrode that is attached to an outer surface of the medical device. The biosensor measures electrochemical changes adjacent to the medical implant. Further, a method of manufacturing a medical implant with a biosensor for use in vivo and a method of integrating a biosensor with a medical implant for use in monitoring conductivity and electrochemical changes adjacent to the medical implant are disclosed.

Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.

The invention discloses a human umbilical mesenchymal stem cell and a preparation method thereof. The human umbilical mesenchymal stem cell is prepared by carrying out aseptic treatment, mechanical shearing, Wharton jelly exposure, collagenase digestion and isolated culture on an umbilical stalk of a healthy fetus by a term abdominal delivery. After freezing and thawing, the cell activity does not decline dramatically, thereby ensuring that the human umbilical mesenchymal stem cell is an ideal seed cell for cellular therapy. The invention also relates to a primitive mesenchymal stem cell prepared by the method, and the primitive mesenchymal stem cell is confirmed as the mesenchymal stem cell by the identification of morphology, immunophenotype and invitro differentiation experiments in accordance with the mesenchymal stem cell standards established by International Society for Cellular Therapy (ISCT). The cell count, cell activity, purity, doubling time and multiplication capacity of the human umbilical mesenchymal stem cell are apparently higher than those of bone marrow-derived mesenchymal stem cell.

A method of forming a tissue equivalent is described. A length of polyester tube is threaded over a mandrel (H) and attached at either end by clips at A and D. A block (F) is then screwed into place. The polyester is then pre-soaked by injecting through Tap (2) an acidified collagen solution for approximately one hour. After a suitable period of time the excess solution is aspirated off. Following this stage, a second, alkaline solution is injected into the apparatus which contains smooth muscle cells (SMC). Thus, neutralisation of the collagen impregnated within the fabric of the tube occurs leading to spontaneous fibrillogenesis within the interstices of the cloth, eliminating the risk of delamination. The apparatus is then incubated. The collagen contracts down onto the fabric tube and the cell-impregnated gel becomes incorporated into the presoaked collagen. The pre-impregnated collagen and the collagen provided in the aqueous mixture contract down as one into a coherent whole with the SMC. The tissue equivalent is then lined with endothelial cells and the apparatus again incubated and fed at increasing intraluminal pressures applied either statically or dynamically. This is believed to cause the vessel to become preconditioned to the pressure it will work under as an implant. This allows organization of the basement membrane which in turn promotes EC attachment and theoretically prevents smooth muscle cell hyperplasia.

Disclosed are methods, compositions, and cells useful for increasing insulin sensitivity, as well as lack of insulin production in a host in need thereof. One aspect of the invention discloses methods of increasing skeletal muscle perfusion through administration of cells capable of directly and/or indirectly stimulatory of angiogenesis and/or vascular responsiveness. Another aspect provides means of increasing sensitivity to insulin through administration of a cell composition capable of integrating into host insulin responsive tissue and upregulating responsiveness either through mobilization of host cells capable of responding to insulin, mobilization of host cells capable of endowing insulin responsiveness on other host cells, exogenously administered cells taking the role of insulin responsiveness, or exogenously administered cells endowing insulin responsiveness on other host cells. Another aspect comprises modifying said host to allow for concurrent insulin sensitization and upregulated production of insulin.

The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies B7 family member B7x as interacting with BTLA to attenuate lymphocyte activity. Methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7x for therapeutic, diagnostic and research purposes are also provided.

A method of stimulating collagen formation in a selected area of mammalian skin in which the selected area is irradiated with a source of visible or near infra-red radiation. The radiation is absorbable by intracellular chromophores to enhance cellular activity and increase collagen formation. A skin treatment device for carrying out the method of the invention is also described.

A ceramic anode structure obtainable by a process comprising the steps of: (a) providing a slurry by dispersing a powder of an electronically conductive phase and by adding a binder to the dispersion, in which said powder is selected from the group consisting of niobium-doped strontium titanate, vanadium-doped strontium titanate, tantalum-doped strontium titanate, and mixtures thereof, (b) sintering the slurry of step (a), (c) providing a precursor solution of ceria, said solution containing a solvent and a surfactant, (d) impregnating the resulting sintered structure of step (b) with the precursor solution of step (c), (e) subjecting the resulting structure of step (d) to calcination, and (f) conducting steps (d)-(e) at least once.

The invention relates to a medical nano-fiber sponge material, of which the porosity is 90-98 percent and the diameter of a nano-fiber is 50-1,000 nanometers. The medical nano-fiber sponge material consists of the following components in percentage by mass: 0.5-8.5 percent of bioactive glass fine particles, 65-88 percent of gelatin, 0.2-5.0 percent of hyaluronic acid, 0.2-5.0 percent of chitosan and the balance of water. A preparation method of the medical nano-fiber sponge material comprises the following steps of: adding bioactive glass fine particles and ethanol into a gelatin aqueous solution, and stirring uniformly; performing low-temperature phase separation and freeze drying to obtain nano-fiber sponge obtained by compounding gelatin and bioactive glass fine particles; and performing soaking, refrigerating and freeze drying with a hyaluronic acid solution and a chitosan solution in sequence under a negative pressure condition to obtain a porous composite sponge material in which nano-fibers are crosslinked and coated statically with hyaluronic acid and chitosan. The nano-fiber sponge has excellent bioactivity, bacteriostasis and mechanical property, and can be widely applied in the fields of regenerative repair of various skin wounds and skin tissue engineering.

Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.

The invention discloses a natural plant whitening soap, which contains the following components: 9-13% of aloe glue, 25-40% of plant whitening liquid, 40-54% of grease substance, 5-10% of strong base substance, 2-3% of sodium chloride, 0.5-0.8% of fungicide, and 0.2-0.7% of germicide. The soap provided by the invention has functions of diminishing inflammation, sterilizing and protecting the skin, and also has remarkable effects of eliminating speckle and whitening the shin; and the soap has the capabilities of whitening, smoothening and refreshing the skin after used for a long time.

The invention belongs to the field of bone damage repair medicinal materials and particularly relates to a preparation method and application of bone cement containing calcium citrate. The bone cement containing calcium citrate is composed of a solid phase part and a liquid phase part, the solid phase part is formed by compounding the calcium citrate and calcium phosphate salt, and the mass ratio of the calcium citrate to the calcium phosphate salt is (2-5):1; the liquid-solid ratio is (0.5-1.5):1. The bone cement containing the calcium citrate has comprehensive biomedical properties such as good plasticity, bone guidance, bone induction activity, cell activity and good degradation rate and is applicable to the orthopedics department, the thoracic surgery department and shaping and restoration of skull and jaw surfaces.

The present invention is related to a system for the heterologous expression of a monoclonal Antibody (mAb) or a fragment or derivative thereof, said system comprising at least one ciliate host cell, and incorporated, into said ciliate host cell, at least one heterologous nucleic acid molecule encoding for said monoclonal Antibody, or a fragment or derivative thereof.

The invention relates to a porous bacterial cellulose skin repair material with a density structure and a preparation method thereof. The porous bacterial cellulose skin repair material with the 'upper dense and lower loose' structure similar to human skin is prepared by controlling the culture condition of bacterial cellulose and adding sustained-release microspheres in the culture process. A loose layer is tightly combined with a dense layer, so that obvious physical layering is avoided, and the structural continuity is good; and gradient changes of the structures are produced in the loose layer and the dense layer, and multiple pores distributed uniformly are formed in the loose layer, so that the upper dense and lower loose gradient structure of the human skin is simulated to the utmost degree. Cells easily enter the material, the healing period of a wound is obviously shortened, and proliferation of healed scars is effectively reduced; and good air permeability and water holding property of the bacterial cellulose are kept, the wound surface can be kept in a wet environment, and healing of the wound surface is facilitated. The forming process is simple, the culture period is short, the preparation process is environment-friendly, simple, convenient and quick, and the preparation cost is low.

The invention aims to provide an efficient culture method of CIK cells. The prepared CIK cell has the characteristics of high multiplication speed, large cell quantity, high cell viability, high killing capacity on cancer cells and the like. The efficient culture method mainly characterized in that a culture flask coated with laminin and fibronectin is used for culturing PBMCs (peripheral blood mononuclear cells), and the cells can be in a half-adherence state by means of the absorption effect of the two kinds of protein, accordingly, the cells can be stimulated by various factors, and the two kinds of protein can promote CIK cell multiplication; and with the adoption of an anti-CD28 monoclonal antibody, the co-stimulation signal of a T cell subset in the CIK cells can be stimulated, and the activation of the CIK cells is promoted. So far, a research report on jointly using laminin, fibronectin and the anti-CD28 monoclonal antibody to prepare the CIK cells is absent. The method for increasing the cell number and improving the killing activity by adding the three factors during preparation of the CIK cells is firstly provided.

The invention discloses a serum-free and DMSO-free cell cryopreservation solution, which comprises a 16.762-16.825 g/L DMEM/F-12 basal culture medium, 32-34 mg/L cytokines, 0.2-0.8 mg/L hydroxyethyl starch, 1-3 mg/L vitamins, 0.15-0.16 g/L antibiotics, 5-6 mg/L protein polypeptide, 1-4 mg/L lipids and a 0.1-0.41 g/L intracellular and extracellular cryoprotectant. According to the technical scheme,the obtained cell cryopreservation solution does not contain serum or DMSO components, the components of the formula are determined, the cell cryopreservation solution has high biological safety andclinical application prospects, and the cell cryopreservation liquid has a cell recovery survival rate of more than 85%, can maintain good cell activity and good physiological characteristics, and issuitable for the related research fields of primary cells and stem cells.

The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject. The present invention also relates to the use of PGC-1 expression levels to determine the safe dosage range for known or putative respiration uncoupling agents for use as anti-obesity therapeutics. The present invention further relates to methods for identifying new compounds that have respiration uncoupling activity.

The invention discloses a culture method for restoring totipotency of a mesenchymal stem cell. The method for restoring totipotency of a mesenchymal stem cell, provided by the invention, comprises the following steps: 1) performing hanging-drop culture on an in-vitro mesenchymal stem cell with reduced totipotency, thus obtaining a hanging-drop cultured cell; and 2) further performing suspension culture on the hanging-drop cultured cell, thus realizing totipotency restoration of the mesenchymal stem cell. The experiment of the invention proves that, according to the method for restoring totipotency of a mesenchymal stem cell (specifically 3D culture), after the mesenchymal stem cell (in-vitro mesenchymal stem cell with reduced totipotency) subcultured multiple times is subjected to 3D culture treatment, the increased volume is gradually restored, the cell viability is enhanced, the cloning capability and differentiation capability are enhanced, and the paracrine action is also improved, thereby activating the aged mesenchymal stem cell and restoring the characteristics of the stem cell.

The invention relates to the technical field of biology, provides a stem cell transport protection solution and particularly relates to an adipose-derived mesenchymal stem cell transport protection solution suitable for long-distance transport. The stem cell transport protection solution is prepared from 10 to 30 percent DMSO (dimethyl sulfoxide), 50 to 150 mu g/mL streptomycin, a 50 to 80 percentDMEM (Dulbecco modified eagle medium) and 8 to 20 percent HES (hydroxyethyl starch). The adipose-derived mesenchymal stem cell transport protection solution has the advantages that the stability of cells and the activity of the cells may be maintained, and convenience is brought to storage and long-distance transport.